Why the study?
Does in vivo administration of high-dose hydroxyurea affect concanavalin-A-induced T-cell proliferation and TCGF production in mouse spleen T lymphocytes?
Does in vivo administration of high-dose hydroxyurea affect concanavalin-A-induced T-cell proliferation and TCGF production in mouse spleen T lymphocytes?
High-dose hydroxyurea depletes short-lived peripheral splenic T lymphocytes, particularly Lyt 2+ cells and those involved in TCGF production.
High-dose hydroxyurea depletes splenic T cells in mice; leaves open effects on human immunity or therapy.
The effects of eliminating cycling precursors by in vivo administration of high doses of hydroxyurea (HU) in populations of mouse spleen T lymphocytes were studied by membrane immunofluorescence identifying mature Thy 1+, Lyt 2- and Lyt 2+ cell populations and mitogen-induced T-cell growth factor (TCGF) production or reactivity to TCGF. HU treatment results in a sharp decrease in the total number of T cells in mouse spleen, indicating that about 50% of peripheral splenic T lymphocytes have a short survival time in vivo. This depletion is more marked for Lyt 2+ cells than for Lyt 2- cells. The decay of TCGF-reactive spleen cells after drug administration is similar to that of the overall spleen T-cell population. Conversely, production of TCGF induced by concanavalin A is predominantly affected by HU treatment, indicating a shorter life span of the cell(s) involved in TCGF production.
No takes yet. Share an insight, caveat, or question.
Rocha et al. (1984) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: